Across TCGA pan-cancer cohorts, LINC01222 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC01222’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LINC01222 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01222 is over-expressed in tumor.
KIRC are the cancer types where LINC01222 tumor–normal differential expression is most reproducible.